Allarity Therapeutics A/S expands its stenoparib license rights to include anti-viral uses.

Allarity Therapeutics A/S announced that it has amended its license agreement with Eisai Co., Ltd. to expand Allarity’s field-of-use to include anti-viral uses of Stenoparib (formerly E 7449). Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment. With the amendment to the license, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.The expansion of the field-of-use rights will support Allarity in its advancement of Stenoparib as a potential anti-viral therapy for COVID-19. The Company has previously announced positive pre-clinical studies showing that Stenoparib has inhibitory activity against Coronavirus as a single agent, and in combination with remdesivir. Based on those results, the Company has submitted a phase II/III protocol through the BARDA portal to be an arm in the NIH ACTIV clinical trials, a part of the Operation Warp Speed. Stenoparib is currently being evaluated for the treatment of advanced ovarian cancer in a DRP-guided Phase II clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) using a DRP companion diagnostic to guide patient enrollment and improve therapeutic outcome. The drug has been tested in over 60 patients to date and is demonstrated to be safe and well tolerated.